A large, abstract graphic composed of many thin, white, curved lines that create a sense of depth and movement, resembling a stylized leaf or a flowing ribbon. It is positioned behind the main text.

Revolutionizing indoor health through *light*

TSX-V : UVC

Investor presentation

LEGAL NOTICE

Important *disclosures.*

FORWARD-LOOKING INFORMATION

This presentation contains "forward-looking information" within the meaning of applicable Canadian securities laws and "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 (collectively, "forward-looking statements"). All statements other than statements of historical fact are forward-looking, including, without limitation, statements regarding product development plans, regulatory pathways, market opportunity, manufacturing capacity, partnership prospects, Far-UVC commercialization timelines, and the company's pro-forma capital structure following listing on the TSX Venture Exchange.

Forward-looking statements are based on assumptions and estimates management believes reasonable as of the date hereof. Actual results may differ materially due to risks including, but not limited to, regulatory delays, product development risk, competitive pressure, supply-chain disruption, customer adoption rates, capital market conditions, and the risks set forth in the company's continuous disclosure record on SEDAR+. The company undertakes no obligation to update forward-looking statements except as required by law.

NON-IFRS MEASURES

Certain financial measures referenced herein — including target gross margin, target unit pricing, serviceable addressable market, and bottom-up revenue path — are not recognised under International Financial Reporting Standards. Such measures do not have standardised meanings under IFRS and may not be comparable to similarly titled measures presented by other issuers.

INDUSTRY & MARKET DATA

Market data, statistics, and forecasts cited herein are derived from third-party sources, internal estimates, and management assumptions. While the company believes such information to be reliable, it has not been independently verified. Statements regarding market size, penetration rates, competitive positioning, and the performance of competing products reflect management's views and may not be representative of actual outcomes. Independent third-party validation referenced (including the University of Leeds aerobiology study) reflects testing conducted under specified laboratory conditions; real-world performance may vary.

NO OFFER OR SOLICITATION

This presentation is for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy, any security in any jurisdiction in which such offer or solicitation would be unlawful. Any offer or sale of securities will be made only by means of a prospectus, offering memorandum, or subscription agreement filed or delivered in accordance with applicable securities laws.

U.S. SECURITIES ACT RESTRICTIONS
CONFIDENTIALITY

The securities of the company have not been and will not be registered under the U.S. Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold within the United States or to U.S. persons (as defined in Regulation S) absent registration or an applicable exemption. This presentation is strictly confidential; reproduction or distribution is prohibited without prior written consent.

THE PROBLEM

Indoor spaces are making people sick, and the world is finally *demanding a solution.*

THE COST OF INACTION

10M+

Hospital-acquired infections every year. More than car accidents globally.

\$100 B+
ANNUAL BURDEN

235 M
SURGERIES AT RISK / YR

5→30 %
UV PENETRATION BY 2030

WHY NOW
FOUR CONVERGING FORCES

2024-26
INFLECTION

- 01 Indoor air is a health crisis
HAIs kill more people than car accidents. Indoor transmission drives pandemic economics.
- 02 Standards are tightening
WHO & CDC raised clean-air targets in 2023-24. ASHRAE 241 sets new clean-airflow rules.
- 03 Canada now mandates UV IN FORCE
Canada's mandate CSA Z317.12:25 is live. 2-3 years ahead of global adoption.
Health Canada approval = proof-point for international buyers.
- 04 Liability drives urgency
7 certified class actions / 200+ facilities / \$100M+ active claims. Procurement converting to signed contracts.

OUR TECHNOLOGY PLATFORM

Two pillars of *innovation*.

Comprehensive lighting solutions that save energy and protect health through our mastery of the light spectrum.

HEALTH CANADA REGISTERED

19+ PATENTS

100% MADE IN CANADA

UPPER-ROOM GUV

99.7% PATHOGEN KILL

FAR-UVC

PRE-COMMERCIAL / Q1 2027

Disinfectant light, deployed today.

Proven upper-room germicidal UV. Health Canada registered for human-safe pathogen elimination in occupied spaces. Validated by the University of Leeds as the best-performing UV device tested in their aerobiology chamber.



Human-safe disinfection at scale.

Breakthrough 216 nm Far-UVC, IP owned outright by Illumisoft, not licensed excimer. Cannot penetrate human skin or eyes; unlocks continuous disinfection in occupied spaces conventional GUV physically cannot reach.



201-1,994
EACH / LEEDS

99.7 %
KILL RATE

24 day
HOSPITAL PAYBACK


70x
Vs. EXCIMER POWER

216 nm
PEAK EMISSION

Q1 2027
COMMERCIAL TARGET

THE TECHNOLOGY

The science of UVC is proven. The *problem*, until now, was human safety.



FOUNDATION

01 / 03

UVC destroys pathogens, physically, not chemically.

Short-wavelength UV breaks apart the DNA and RNA of viruses, bacteria, and fungi. There is no chemical residue, and no resistance can develop, pathogens cannot evolve around physics.

MECHANISM

DNA / RNA dimerization

SANILUME / 254 NM

02 / 03

Upper-room germicidal UV.

Mounted above head-height so occupants never encounter the direct beam. Ceiling fans continuously draw indoor air through the germicidal field, delivering 1,994 equivalent air changes per hour.

STATUS

Shipping today

SANILUX / 216 NM

03 / 03

Far-UVC, human-safe disinfection.

At 216 nm the light still kills pathogens, but cannot penetrate human skin or the tear layer of the eye. Solid-state, 70x more powerful than excimer, unlocks continuous disinfection in occupied spaces.

STATUS

Pre-Commercial Q1 2027

PRODUCT PORTFOLIO

Our product *family.*



LED LIGHTING

REVENUE PRODUCING

ECOWing

Diffused LED lighting. Industry-leading commercial LED retrofit; 34 of Top 50 DLC products globally, with patented optical film that eliminates glare without sacrificing efficiency.

167 lm/W
PEAK EFFICACY

60-75%
ENERGY SAVINGS

5 min
INSTALL TIME

50,000 h
LIFESPAN

GERMICIDAL UV

ACTIVE REVENUE

SaniLume

Upper-room Germicidal UV. The only Health Canada-registered upper-room GUV device. University of Leeds validated as the best-performing UV device tested.

99.7%
PATHOGEN KILL

201-1,994
EACH

750 ft²
COVERAGE

24 days
HOSPITAL PAYBACK

FAR-UVC

LAUNCHING SOON

SaniLux

Far-UVC at 216 nm, 70x more powerful than excimer alternatives at one-fifth the cost. Proprietary nanoengineered technology, safe for continuous human exposure.

70x
MORE POWERFUL

< 1 min
KILL TIME

216 nm
PEAK EMISSION

10,000 h
LIFESPAN

ACTIVE REVENUE

254 NM

HEALTH CANADA REGISTERED

The most effective upper-room germicidal UV device in the market.



SANILUME

Independently validated at the University of Leeds aerobiology chamber, 2022.

201-1,994

EQUIV. AIR CHANGES / HR


99.7%

ELIMINATION RATE


750 ft²

COVERAGE


CDC ventilation baseline: 6-12 eACH




Aerosol Pathogens Exhaled




Modeling of Pathogen Spread



SaniLume



UVC Energy Field



Concentration of Contaminants
More
Less

CFD aerosol modelling, Illumisoft. Pathogens spread through a classroom without the device; SaniLume's upper-room UVC field eliminates them before they reach occupants.

INDEPENDENT VALIDATION: UNIVERSITY OF LEEDS

The most powerful upper-room GUV device on the market.



The best performing UV device that has been tested in the aerobiology chamber at the University of Leeds to date.

DR. LOUISE FLETCHER
SCHOOL OF CIVIL ENGINEERING, UNIVERSITY OF LEEDS · AEROBIOLOGY CHAMBER, AUGUST 2022

PATHOGEN ELIMINATION, TESTED IN LEEDS AEROBIOLOGY CHAMBER

35.6 M³ / 6 ACH BASELINE / 50% RH

PSEUDOMONAS AERUGINOSA
Antibiotic-resistant / hospital-acquired infection

STAPHYLOCOCCUS AUREUS
MRSA family, common surgical-site pathogen

PHI-6 BACTERIOPHAGE
Enveloped RNA virus, COVID-19 surrogate

99.7%

99.2%

99.1%

EQUIVALENT AIR CHANGES / HOUR 1,994

EQUIVALENT AIR CHANGES / HOUR 744

EQUIVALENT AIR CHANGES / HOUR 661

ORDER-OF-MAGNITUDE CONTEXT

CDC ventilation baseline 6–12 eACH ASHRAE 241 high-tier ~30–60 eACH SaniLume chamber **1,994 eACH**

COMMERCIAL CASE

Validated *economics*. Mandatory *demand*.

From the CHAIR national economic model, to the unit economics of a tertiary deployment, to the bottom-up North American hospital SAM.

CHAIR MODEL · HOSPITAL SECTOR

The national policy case.

\$47.7B

ANNUAL SOCIETAL VALUE

Returned by a national hospital UV deployment program — across treatment costs avoided, bed availability reclaimed, QALY value, and tax revenue protected.

Program investment	\$3.2B
HAIs prevented annually	473,590
Lives saved annually	41,451
National program payback	24 days
30-year ROI	44,741%

Source: CHAIR Coalition for Healthcare Acquired Infection Reduction, National EIP Program Model. Canadian HAI rate: 10.5% (worst in OECD) vs. 3% best practice.

TERTIARY DEPLOYMENT · Q2 2026

Validated by deployment.

972

UNITS TO OUTFIT A SINGLE FACILITY

A major Canadian tertiary facility — expected Q2 2026 deployment. The first real-world calibration of unit economics at scale, against the bottom-up SAM model.

Units required	972
Per unit price	\$3,500
Facility deployment value	~\$3.4M
vs. modeling assumption	9.7× anchor

This deployment requires 9.7× the per-hospital units assumed in the SAM model. The tertiary facility benchmark suggests the 100-unit anchor used in our bottom-up math is materially conservative.

PHASE 1 SAM · N. AMERICAN HOSPITALS

Bottom-up opportunity.

\$117M

PHASE 1 HOSPITAL REVENUE / 5% PENETRATION

Conservative bottom-up across the North American hospital channel. Adjacent verticals (LTC, education, government, commercial) represent material upside not yet captured.

N. American hospitals	6,700
Avg. units / hospital	100
Per unit price	\$3,500
Hospital TAM (gross)	\$2.35B
Target penetration	5%

100 units/hospital is a deliberately conservative anchor. Anchor-customer deployment data suggests tertiary facilities range materially higher.

SANILUX

COMING SOON FAR-UVC / 216 NM

A fundamental *shift*, not an increment.

Proprietary 216 nm solid-state Far-UVC. IP owned outright by Illumisoft, not licensed excimer.

70x
MORE POWERFUL

<1min*
KILL TIME

Human-safe at 216 nm; cannot penetrate skin or eyes. Unlocks continuous disinfection in occupied spaces.



TECHNOLOGY ADVANTAGE

SaniLux vs. conventional Far-UVC, every competitor licenses excimer from *one Japanese supplier*.

R-Zero raised \$170M USD and still cannot serve aviation, transit or commercial, hard excimer power limits. SaniLux is solid-state, Watt-range, owned outright.

METRIC	EXCIMER / USHIO / R-ZERO	ILLUMISOFT SANILUX	ADVANTAGE
Power output	Milliwatt range	Watt range / 70× higher	70×
Kill time	60-90 min per cycle	Under 1 min (at peak)*	70-90× faster
Unit price	\$1,000-\$5,000+	~\$350 target	66-77% lower
Product lifespan	~1,000 hours	10,000+ hours	10× longer
Aviation / transit	No / insufficient power	Yes / market-creating	\$200B+ new

* SaniLux <1 min kill time is at peak output; regulatory limits require lower irradiance in occupied spaces.

INDUSTRY VALIDATION / BLUEPRINT BIOSECURITY

Why Far-UVC is the *future* of indoor air.

Independent assessment by Blueprint Biosecurity, the leading nonprofit advancing pandemic-preparedness infrastructure. Their 266-page Blueprint for Far-UVC report (2025) is the definitive technical and policy review of the field.

"Far-UVC represents one of the highest-leverage funding opportunities in airborne disease and pandemic prevention that we are aware of."

Blueprint for Far-UVC, Blueprint Biosecurity (2025)

THE BLUEPRINT'S THREE-PART ARGUMENT

01 Categorically different from conventional UV.

Far-UVC is strongly absorbed by the outer protein layer of skin and eyes, enabling pathogen inactivation at human exposure limits that conventional GUV cannot achieve — unlocking continuous disinfection in occupied spaces.

02 Pandemic prevention infrastructure.

Silent, energy-efficient, commercially viable at scale, less vulnerable to resistance than pharmaceuticals, and deployable in advance of an outbreak — to help prevent a pandemic from occurring in the first place.

03 Cost-benefit profile is exceptional.

Independent peer-reviewed analyses cited by Blueprint show 10:1 ROI for ASHRAE 241 air-cleaning compliance, and a 30–290× benefit-cost ratio for Far-UVC in indoor public spaces during normal respiratory illness seasons.

REVENUE PRODUCING DIFFUSED LED

ECOWing

60-75% *less energy.*

167 lm/W of DLC-listed efficiency, engineered and manufactured in Ottawa. The beachhead that opens every door.

#1
DLC RANKING

34/50
TOP DLC
FIXTURES

17
PATENTS

40-55%
GROSS MARGIN



ECOWING DIFFUSED LED

Every ECOWing install is a warm cross-sell for SaniLume & SaniLux, riding existing relationships:



MARKET OPPORTUNITY

\$248B global market / bottom-up path to \$100M revenue.

INFECTION CONTROL 2024

\$248B

BY 2034

\$473B

CAGR

6.7%

UV PENETRATION

5→30%

N. AMERICA SHARE

40-49%

SANILUME / GUV

TODAY

\$9.7B

Hospital SAM / 230K × 12 units

1% penetration = \$96M annual revenue. CSA mandate = mandatory procurement today. HAI control \$38.5B → \$82B by 2032.

SANILUX / FAR-UVC

UNPRICED OPTION

\$5.25B

Phase 1 / hospitals + aviation

Phase 2: schools + commercial = \$35B+. 30,000 aircraft × 20 units = 600K units. Long-term: standard infrastructure like fire suppression.

ECOWING / LED

ESTABLISHED REVENUE

~\$8B

N. American retrofit SAM

Revenue-generating today / proven foundation. Top 5 players = 20% share / highly fragmented. Cross-sell gateway into SaniLume & SaniLux.

TRACTION / TRUSTED BY INDUSTRY LEADERS

Government, healthcare, real-estate, *already on board.*

In partnership with Health Canada and the NRC to help establish Workplace 3.0 standards for Federal buildings.


<p>REGULATORY</p>	<p>R&D PARTNER</p>	<p>REAL ESTATE</p>	<p>REAL ESTATE</p>	<p>REAL ESTATE</p>	<p>FEDERAL</p>
<p>HOSPITAL PILOT</p>	<p>STANDARDS BODY</p>	<p>RANKINGS</p>	<p>COALITION</p>	<p>BOARD CONNECT</p>	<p>INDUSTRY AWARD</p>

<p>ACADEMIC</p> <p>University of Leeds</p> <hr/> <p><i>"Best performing UV device ever tested", aerobiology chamber, 2022.</i></p>	<p>REGULATORY</p> <p>Health Canada</p> <hr/> <p>Only registered upper-room GUV device in Canada.</p>	<p>INDUSTRY</p> <p>DesignLights Consortium</p> <hr/> <p>#1 energy-saving retrofit / 34 of top 50 fixtures globally (60,000+ ranked).</p>	<p>COALITION</p> <p>Blueprint Biosecurity</p> <hr/> <p>Advocates Far-UVC as critical pandemic-preparedness infrastructure.</p>	<p>AWARD</p> <p>IES</p> <hr/> <p>Illuminating Engineering Society / UV Technology Advancement recognition.</p>
---	---	---	---	---

GO - TO - MARKET & SCALE

Canada first. *The world follows the standard.*

PHASE 01 / NOW	ACTIVE	PHASE 02 / 12-24 MO	QUEUED	PHASE 03 / 24+ MO	SCALE
Dominate Canada		US & International		SaniLux at scale	
CSA mandate delivers immediate SaniLume procurement across the public sector.		Health Canada registration is the proof point international buyers and regulators are waiting for.		Far-UVC unlocks aviation, transit, and commercial spaces. Capital-light licensing preserves IP value.	
CHANNEL	Direct + govt	PATHWAY	FDA + EU streamlined	LAUNCH	Aviation, transit
TAM	23,500+ facilities	SEGMENTS	Healthcare, education	MODEL	Licensing, IP core
CAPACITY	10-15K u/yr, Ottawa	CAPACITY	50K u/yr target	ROYALTY	5-10% of revenue



MAJOR STRATEGIC INVESTMENT

Backed by *global visionaries.*

Chris Anderson (Founder of TED) and Rob Reid (Creator of Rhapsody) have made a significant ownership commitment through their joint venture, Resilience Reserve LLC.

OWNERSHIP STAKE

19.43%

Chris Anderson & Rob Reid / Resilience Reserve LLC



Chris Anderson

Founder & Curator of TED

"Illumisoft's existing and upcoming products promise to significantly dampen the spread of respiratory diseases in healthcare facilities, schools, and beyond. This could greatly enhance social resilience at all levels of global income."



Rob Reid

Creator of Rhapsody / After On Podcast

"Illumisoft could soon revolutionize the use of tuned and targeted light as a weapon against disease. Far-UVC is the most promising biosecurity technology I have encountered in two decades of investing at the frontier of science and venture."

ABOUT ILLUMISOFT

Ottawa-built. Engineered across every wavelength that matters.

A Canadian photonics company with two commercial product lines, one breakthrough R&D program, and a leadership team drawn from public markets, semiconductor physics, and global-health venture capital.

FOUNDED

2014, Ottawa

Designed, engineered, manufactured in Canada

TECHNOLOGY

Diffused LED + Germicidal UV

19+ patents, 2 commercial lines, 1 R&D breakthrough

LISTING

TSX-V : UVC

REGULATORY

Health Canada registered

First device under CSA Z317.12:25 UV mandate

LEADERSHIP: EXECUTIVE TEAM + BOARD



CHIEF EXECUTIVE OFFICER

Brett Nicholds

Led Illumisoft from pre-commercialisation to national distribution



CHIEF TECHNOLOGY OFFICER

Dr. Michael Johnson

Physics PhD, ASU. Former Motorola semiconductor. Architect of SaniLux



CHIEF FINANCIAL OFFICER

Ali Pickett

15+ yrs financial leadership. Managed \$8B+ in assets. TSX-V experience



PRESIDENT

Graham Ballachey

Engineer and executive with a proven track record of driving results.



CHAIRMAN

Ehsan Agahi

Zephyr Venture Partners, biotech & life-sciences M&A



DIRECTOR

Cameron Groome

CEO Microbix Biosystems (TSX), advised Global Affairs Canada



DIRECTOR

Ryan Adam

Wellington DuPont, former PMO Western Canada & Natural Resources

CAPITAL STRUCTURE

PRO-FORMA SHARES OUTSTANDING

Capitalization at listing.

Claranova shares to shareholders	22,261,805
Gstaad post-consolidation (5:1)	1,881,667
Concurrent financing (up to \$7M @ \$0.30)	23,333,334
Finder warrants	425,390
Bridge debenture (due May 4, 2026)	\$333,333

FULLY DILUTED / MAX FINANCING

~47,476,806

USE OF PROCEEDS

Capital deployment.

Manufacturing & inventory scale	~35%
Sales & channel expansion (CA / US)	~25%
SaniLux R&D / prototype completion	~20%
Working capital & G&A	~15%
Listing & transaction costs	~5%

Illustrative allocation, subject to revision based on final concurrent financing quantum, board allocation policy, and disclosure in the company's listing prospectus / final offering documents.

INVESTMENT THESIS

Six reasons. *Why illumisoft.*

TODAY

MANDATORY

Mandatory market, today

Canadian CSA Z317.12:25 mandates UV. SaniLume is the only registered device. Structural demand, not cyclical.

VALIDATED

100x

Validated performance

Leeds: 1,994 eACH vs. 0.003-17 for all other devices. Peer-reviewed, independent science.

UNPRICED

\$200B+

SaniLux / \$200B+ option

70x more powerful than excimer. R-Zero raised \$170M for an inferior product. Unpriced at listing.

BACKED

19.43%

Mission-aligned backers

Chris Anderson (TED, \$6.6B+ Audacious) and Rob Reid chose Illumisoft from every technology globally.

TAILWINDS

\$112T

Two existential tailwinds

Pandemic preparedness (\$12T COVID cost) and AMR (\$100T, 4.95M deaths/yr) both drive procurement.

ENTRY

GENERATIONAL

Generational entry point

~\$14.2M CAD at max financing. Active govt contracts. Health Canada registered. 19+ patents. TSX-V : UVC.



Proven technology. Mandatory
market. Generational entry point.

WEB
illumisoft.com

CONTACT
info@illumisoft.com

REGISTERED
Ottawa, Canada

TICKER
TSX-V : UVC